CLASS 3 RECALL - METHADONE TAB 5MG (PHYSEPTONE 5MG TABLETS)

Martindale Pharma is recalling the below batch of Methadone 5mg tablets as a precautionary measure due to the discolouration of the PVdC film in a small number of blister pockets

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-martindale-pharma-an-ethypharm-group-company-methadone-5mg-tablets-slash-physeptone-5mg-tablets-el-21-a-slash-31?utm_medium=email&utm_campaign=govuk-notifications&utm_source=c480fd76-d520-4a64-9570-f410b38c7b35&utm_content=immediately   

This product is a Schedule 2 Controlled Drug, so please use the Returns Portal for any recalled stock you may need to return to ensure there is authorization to return. When you are completing the portal if you are returning a split pack Please include exact number of tablets you are returning. If you are unable to use the Returns Portal please call Customer Services for assistance.

Further Information

For more information please contact:

Customer Services for stock control enquiries: Licensed@ethypharm.com

or for Medical Information enquiries: medinfo@martindalepharma.co.uk

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

If you have any questions, then please contact your local Service Centre Customer Services team.

CLASS 2 RECALL - IKERVIS EYE DROPS 0.1% & VERKAZIA 0.1% EYE DROPS UD

SANTEN Oy (trading as Santen UK Limited) are recalling the below batches of products as a precautionary measure due to detection of particles/crystals of the active pharmaceutical ingredient ciclosporin. These particles have been detected following microscopic evaluation during stability monitoring

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-santen-oy-trading-as-santen-uk-limited-and-parallel-distributor-ikervis-1-mg-slash-ml-eye-drops-emulsion-and-verkazia-1-mg-slash-ml-eye-drops-emulsion-el-21-a-slash-30?utm_medium=email&utm_campaign=govuk-notifications&utm_source=ed7060ba-57ef-42eb-89b1-ac5b77c8be8a&utm_content=immediately  

Alliance do not stock the above products so we will not be accepting Customer returns on this recall.

Further Information

Santen UK Limited

For more information, please contact +44 (0)1727 615 110 or email enquiries@santen.co.uk

For medical information queries, please contact 0345 075 4863 or email medinfo@santen.co.uk

For supply queries, please contact AAH Customer services at 0344 561 8899

Orifarm A/S

For all enquiries please contact:

Paul Tobin (Responsible Person) on 07583577513 or email at paul.tobin@orifarm.com

Steven Cross (UK Parallel Import Sales Manager) on 07498975920 or email at steven.cross@orifarm.com

If you have any questions, then please contact your local Service Centre Customer Services team.

Class 4 Drug Caution in use - SLENYTO 1 MG AND 5MG PROLONGED RELEASE TABLETS

Flynn Pharma Ltd, distributors of Slenyto 1 mg and 5mg prolonged release tablets would like to notify you of an error with the patient information leaflets (PILs) that have been packaged in the below batches of products. These were an older version of the PIL which did not include the most up to date safety information

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-slenyto-1-mg-and-5mg-prolonged-release-tablets-distributed-by-flynn-pharma-ltd-el-21-a-slash-29?utm_medium=email&utm_campaign=govuk-notifications&utm_source=918a7eae-bd86-4833-899a-5114d92b0980&utm_content=immediately      

Alliance healthcare do not stock this product therefore we are not accepting stock returns.

Further Information

For more information, medical information queries or replacement PIL enquiries, please contact:

Flynn Pharma Ltd Medical Information Department on 01438 727822, email – medinfo@flynnpharma.com.

For stock control queries, please contact: Flynn Pharma Ltd on 01438 727822

If you have any questions, then please contact your local Service Centre Customer Services team.

COMPANY-LED DRUG ALERT - DOTAREM SOLUTION FOR INJECTION (10ML VIAL)

Guerbet Laboratories Ltd is recalling the below batches of Dotarem 10ml vials, due to the potential risk of a sterility break, based on the evidence of external leaks of the solution (dry product on the external surface of the vials)

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/company-led-medicines-recall-dotarem-solution-for-injection-10ml-vial-pl-12308-slash-0016?utm_medium=email&utm_campaign=govuk-notifications&utm_source=6e2cf2cc-77cb-4717-a214-e7df6d710c9c&utm_content=immediately        

Alliance do not stock this product and therefore we are not accepting stock returns.

Company Contact for medical information enquiries

For medical information enquiries, please contact James Bradley (GDP RP):

james.bradley@guerbet.com

Company Contact for stock enquiries

For stock information enquiries,

UK Customer Services

uk.sales@guerbet.com

If you have any questions, then please contact your local Service Centre Customer Services team.

CLASS 2 RECALL - COLD & FLU RELIEF CAPSULES (GSL) – VARIOUS LIVERIES

Perrigo are recalling the below batches of Cold & Flu Relief Capsules (GSL) – Various Liveries, due to an error on the leaflet and carton for the products as noted above. The leaflet and carton incorrectly states that for Adults, the elderly and children 12 years and over, the dose should be 2 capsules every 4 to 6 hours as required, up to a maximum of 12 capsules in any 24 hour period. The leaflet and carton dosage instructions are those which were in use prior to the paediatric paracetamol posology update implemented by the MHRA

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-cold-and-flu-relief-capsules-gsl-various-liveries-wrafton-laboratories-limited-trading-as-perrigo-el-21-a-slash-28?utm_medium=email&utm_campaign=govuk-notifications&utm_source=f44f6fc5-9c7f-4cc3-b3ab-df07db229afc&utm_content=immediately   

Further Information

For more information, please contact: Perrigo Customer Services Team on 0203 598 9603 or UKLOCustomerService@perrigo.com

For stock control queries, please contact: Perrigo Service Team on 01226 704711 or customerservice@perrigouk.com

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

If you have any questions, then please contact your local Service Centre Customer Services team.

Class 4 Drug Caution in use - MITOCIN (MITOMYCIN) 20MG POWDER FOR SOLUTION FOR INJECTION/INFUSION

Vygoris Limited has informed the MHRA that some vials of Mitocin 20mg powder for solution for injection/infusion or intravesical use may contain subvisible particles above the current specifications after reconstitution (>10µm: NMT 6000/vial), initially identified during stability studies. Vygoris Limited has confirmed that a single-use filtration device called the Millex® HV (0.45 μm/PVDF) - Syringe Filter will be included in each delivery of the product

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-vygoris-limited-mitocin-mitomycin-20mg-powder-for-solution-for-injection-slash-infusion-or-intravesical-use-el-21-a-slash-27?utm_medium=email&utm_campaign=govuk-notifications&utm_source=23f29568-2411-48f9-bc43-7b69aed25c18&utm_content=immediately                  

This is a caution in use only we are not accepting stock returns.

Further Information

For medical information queries, please contact:

Lucy Owen,

ProductLifeGroup

Tel: +44 (0) 1223 402660

Email: lowen@productlife-group.com

For more information or stock control queries, please contact:

Hussain Tahan

Vygoris Ltd

Tel: 020 3865 1682

Email: qualitylimited@vygoris.com

If you have any questions, then please contact your local Service Centre Customer Services team

CLASS 4 CAUTION IN USE - SYRENIRING 0.12MG/0.015MG 24 HR

Crescent Pharma Ltd has informed us that the Patient Information Leaflet (PIL) within the packs for the below batches is missing important safety relevant text changes

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-crescent-pharma-ltd-syreniring-0-120-mg-0-015-mg-per-24-hours-vaginal-delivery-system-el-20-a-36?utm_medium=email&utm_campaign=govuk-notifications&utm_source=8b7c3acf-aee7-4d91-8b27-85a8e19f72c8&utm_content=immediately               

This may have been supplied by AHDL. Unfortunately we are not providing specific batch information you will  be required to follow the instructions as per the drug alert.

This is a caution in use only we are not accepting stock returns.

For more information or medical information queries, please contact: Crescent Pharma Ltd. Medical Information Department on +00351 214643225, via email on tiago.barca@pharsolution.com or +44 (0) 1256 772740..

If you have any questions, then please contact your local Service Centre Customer Services team.

CLASS 3 RECALL - BIMATOPROST ASPIRE 0.3MG/ML EYE DROPS, SOLUTION IN SINGLE DOSE CONTAINER 0.4ML X 30

Aspire Pharma Limited is recalling the below batches of Bimatoprost Aspire 0.3mg/ml eye drops, solution in single dose container 0.4ml x 30 as a precautionary measure due to the identification of some variability in the thickness of plastic of the single dose containers resulting in some patients finding the containers difficult to squeeze due to increased hardness of individual containers

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-bimatoprost-aspire-0-dot-3mg-slash-ml-eye-drops-solution-in-single-dose-container-aspire-pharma-limited-el-21-a-slash-26?utm_medium=email&utm_campaign=govuk-notifications&utm_source=c124cb76-bb49-44e5-be21-df3473e3acd9&utm_content=immediately  

Further Information

For more information please contact:

Customer Services for stock control enquiries:

Email: customerservices@aspirepharma.co.uk

Tel. 01730 231148

or for Medical Information enquiries:

Email: medinfo@aspirepharma.co.uk

Tel. 01730 231148

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

If you have any questions, then please contact your local Service Centre Customer Services team.

COMPANY LED - IRINOTECAN 200MG/ 260ML IN SODIUM CHLORIDE 0.9% W/V INTRAVENOUS INFUSION AND INFLIXIMAB (REMSIMA) INTRAVENOUS INFUSION IN SODIUM CHLORIDE 0.9%

Qualasept Ltd t/a Bath ASU is recalling a specific batch of Irinotecan 200mg/260mL in sodium chloride 0.9% w/v intravenous infusion and specific batches of Infliximab (Remsima) Intravenous infusion in Sodium Chloride 0.9%w/v due to risks of reduced product quality

MHRA drug alert link https://www.gov.uk/drug-device-alerts/company-led-medicines-recall-irinotecan-200mg-slash-260ml-in-sodium-chloride-0-dot-9-percent-w-slash-v-intravenous-infusion-and-infliximab-remsima-intravenous-infusion-in-sodium-chloride-0-dot-9-percent?utm_medium=email&utm_campaign=govuk-notifications&utm_source=46e56b1e-074c-4df7-b8da-04593bef0bdc&utm_content=immediately     

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

Company Contact for medical information enquiries

For medical information enquiries, please contact Maria Connolly:

Tel: 01225 811131

Maria.connolly@bathasu.com

Company Contact for stock enquiries

For stock information enquiries,

Tel: 01225 811131

customerservices@bathasu.com

CLASS 2 RECALL - CHAMPIX (ALL STRENGTHS) FILM-COATED TABLETS

Champix (varenicline tartrate) is indicated for smoking cessation in adults. Upon request from MHRA, Pfizer Ltd are recalling specified batches (all stock) of products as a precautionary measure due to presence of levels of N-nitroso-varenicline above the acceptable level of intake set by both European Medicines Agency (EMA) and MHRA. The recall is at pharmacy and wholesaler level

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-pfizer-ltd-champix-all-strengths-film-coated-tablets-el-21-a-slash-25?utm_medium=email&utm_campaign=govuk-notifications&utm_source=97cdd42e-9465-4f68-a92e-8ad9b4d937f3&utm_content=immediately   

Please note that we do not stock the PI Livery listed in the attached document from the MHRA and returns will not be accepted.

Further Information

Pfizer is aware of the current supply constraints related to this product and is working to resolve the issue and resume manufacturing. Further updates relating to potential resupply will be communicated in due course.

If you have any questions, then please contact your local Service Centre Customer Services team.

For medical information enquiries, please contact Pfizer Medical Information Department on 01304 616161.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.